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Abstract
Arsenic trioxide (ATO) is an inorganic arsenic derivative that is very effective against acute 
promyelocytic leukemia. However, organic arsenic derivatives (OAD) have a more favorable 
toxicity profile than ATO. We herein characterized dipropil-S-glycerol arsenic (GMZ27), a novel 
OAD. GMZ27 had potent antiproliferative activity against human acute myeloid leukemia (AML) 
cell lines that was higher than that of ATO. In contrast to ATO, GMZ27 only marginally induced 
maturation of leukemia cells and had no effect on the cell cycle. The anti-leukemia activity of 
GMZ27 against AML cells was independent of the presence of the PML–RARα fusion protein. 
GMZ27 dissipates mitochondrial transmembrane potential, and induces cleavage of caspase 9 and 
activation of caspase 3 without altering the expression levels of (BCL-2), BAX and BCL-xl. 
GMZ27 induces the formation of intracellular superoxide, a reactive oxygen species (ROS) which 
plays a major role in the antileukemia activity of this OAD. In addition to ROS generation, 
GMZ27 concomitantly reduces intracellular glutathione which markedly weakens the cellular 
antioxidant capacity, thus enhancing the detrimental intracellular effects of ROS production. These 
results indicate that GMZ27 induces apoptosis in AML cells in a PML–RARα-independent 
fashion, through the induction of ROS production. This activity provides the rationale for the 
testing of GMZ27 in patients with AML.
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Several studies conducted over the past decade established the efficacy of arsenic trioxide 
(ATO) in patients with both newly diagnosed or relapsed acute promyeloytic leukemia 
(APL) (1-3). The success of ATO in inducing high rates of complete remission in patients 
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who have relapsed with this, once highly lethal, leukemia provided the impetus for 
uncovering the specific mechanism of action underlying such dramatic clinical activity. In 
most APL cells, the t(15;17) results in the production of the PML–RARα-Independent 
fusion protein which blocks the cell maturation process (3). Several studies have shown that 
ATO acts on cells through a variety of mechanisms, influencing numerous signal 
transduction pathways and resulting in a wide range of cellular effects which include 
induction of apoptosis, arrest of cell cycle progression, block of differentiation, reactive 
oxygen species (ROS) production, and even inhibition of angiogenesis (3). In PML–RARα-
positive cells, ATO promotes degradation of the PML–RARα protein by targeting the PML 
moiety, which results in therapy-induced restoration of nuclear bodies, leading to cell 
maturation (3-5). The mechanisms involved in ATO-induced nuclear body reformation 
involve the formation of ROS and the direct binding of ATO to PML cysteines. PML 
multimerization and ATO binding represent the primary mechanisms of ATO-induced APL 
cure (3-5). However, clinical use of ATO is limited by cardiovascular, hepatic, 
gastrointestinal and central nervous system toxicity (1, 2, 6, 7). In contrast, organic arsenic 
derivatives (OAD) are much less toxic; in fact, hepatic methylation of inorganic arsenic 
compounds, including ATO, to yield organic derivatives is a mechanism of detoxification 
which makes them promising candidates for treating leukemia and other malignancies with a 
better therapeutic index than ATO (7, 8). Research efforts have been directed towards 
synthesis of OADs with high efficacy towards leukemia cells and low systemic toxicity (8). 
On this basis, we synthesized GMZ27, a novel OAD derived from dimethylarsinic acid. In 
spite of the fact that ATO and OAD are both arsenic derivatives, different mechanisms may 
be utilized by these compounds to exert their antileukemic activity due to important 
differences in their chemical structures. Unveiling the mechanisms of antileukemic activity 
of OAD may be exploited in subsequent clinical studies with these compounds.
Materials and Methods
Cells and chemicals
Human cell lines used in this study included the following: acute promyelocytic leukemia 
NB4 cells, acute myelomonocytic leukemia HL60 cells (both provided by Miloslav Beran 
MD, Ph.D., DVM, The University of Texas M.D. Anderson Cancer Center); human 
leukemic monocyte lymphoma cell line U937 and human chronic myeloid leukemia KBM-5 
cell line, provided by Michael Andreeff, MD, Ph.D., The University of Texas M.D. 
Anderson Cancer Center. HL60, NB4, and U937 cell lines were cultured in RPMI-1640 
medium. All media were supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, 
CA, USA) and penicillin-streptomycin solution (100 U/ml; Gemini Bio-products, 
Sacramento, CA, USA). Cells were cultured at 37°C in a humidified atmosphere containing 
5% CO2. ATO was purchased from Sigma Aldrich (Saint Louis, MO, USA) and dissolved in 
1 M HCl; this stock solution was then diluted as requested. GMZ27 (provided by Ralph A. 
Zingaro, Ph.D., Texas A&M University, College Station, Texas) was dissolved in methanol 
to a stock concentration of 10 mM. Further dilution was achieved by addition of (PBS). N-
Acetyl-L-cysteine (NAC), L-buthionine-[S,R]-sulfoximine (L-BSO), and dithiothreitol 
(DTT) were purchased from Sigma Chemical Co. Toxicity testing of GMZ27 was carried 
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out in 11-week-old Swiss Webster mice (Taconic Laboratory Animals and Services, 
Germantown, NY, USA).
Determination of cell growth
Cell growth was assessed by measuring the number of living cells using the 3-(4,5-
dimethylthia-zol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(MTS) assay. The MTS assay was performed according to the manufacturer’s 
recommendations (CellTiter 96 Aqueous One Solution Reagent; Promega, Madison, WI, 
USA). Briefly, cells were seeded in triplicate in 96-well microtiter plates (BD Falcon, 
Franklin Lakes, NJ, USA) and were incubated in the presence of increasing drug 
concentrations for up to 72 hours. The seeding density utilized depended on the cell line 
used and varied from 0.05-0.4×106/well. Upon drug exposure, the level of growth inhibition 
as evidenced by the dye color change was quantified by measuring the absorbance at 490 nm 
and was expressed as a percentage of the control growth (no drug in the sample). The half 
maximal inhibitory concentration (IC50) value was then determined. The number of live 
cells was determined by the Trypan blue assay. Briefly, cells were plated at 0.5×106/ml and 
cultured for up to 72 hours in 24-well plates at different concentrations of ATO or GMZ27. 
Cells were then washed in PBS and were mixed with an equal volume of saline containing 
0.4% Trypan blue dye (GIBCO-BRL, Gaithersburg, MD, USA). Dead cells fail to exclude 
the dye and can be counted by discrimination from unstained, live cells. Survival was 
calculated in terms of total live cell numbers in each well and was then expressed as a 
percentage of the survival in control wells.
Annexin V and propidium iodide (PI) staining
After treatment with arsenic derivatives for different periods of time, cells were washed in 
Ca2+-free PBS and resuspended in 100 μl of binding buffer (10 mM 4-[2-hydroxyethyl]-1-
piperazineethane-sulfonic acid, pH 7.4; 0.15 M NaCl; 5 mM KCl; 1 mM MgCl2; 1.8 mM 
CaCl2) to which annexin V- fluoroisothiocyanate (Travigene) had been added. Cells were 
then incubated for 15 minutes in the dark at room temperature. After incubation, cells were 
washed in 2 ml PBS and then resuspended in 0.5 ml of binding buffer. After the addition of 
PI, the binding of annexin V to apoptotic cells was analyzed on a flow cytometer (FACScan; 
Becton Dickinson, Mountain View, CA, USA) by using the program CellQuest (Becton 
Dickinson).
In vivo toxicity
Normal female Swiss-Webster mice were divided into treatment groups which received 
different single injections on a 10 mg-dose escalating schedule with doses ranging from 0 
(control) to 150 mg/kg with each group consisting of five mice receiving the same single 
dose injection. Drug toxicity was measured as the LD50, which was the dosage at which 
50% of mice in the group were killed.
Detection of caspase activity
To monitor caspase activity by flow cytometry, the fluorogenic substrate PhiPhiLux G1D2 
(Oncoimmunin, Gaithersburg, MD, USA) was used. PhiPhiLux G1D2 is a substrate for the 
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detection and measurement of caspase- 3 and caspase3-like activities in living cells. After 
treatment with arsenic derivatives for different lengths of time, cells were washed in Ca2+-
free PBS, resuspended in 25 μl of substrate solution, and were incubated for 1 hour at 37°C 
in the dark. After incubation, cells were washed and resuspended in PBS. PI was added to 
exclude necrotic cells during analysis. Cell samples were then run on a flow cytometer 
(FACScan; Becton Dickinson) and data obtained were analyzed with CellQuest software 
(Becton Dickinson).
Mitochondrial inner transmembrane potential dissipation
After treatment with arsenic compounds for the indicated time, cells were incubated with 
submicromolar concentrations of MitoTracker probes to evaluate the changes in the potential 
of the mitochondrial membrane. MitoTracker probes passively diffuse across the plasma 
membrane and accumulate in mitochondria. Treated cells were stained with two probes: 
MitoTracker Red (CMXRos; Molecular Probes, Eugene, OR, USA) and MitoTracker Green 
FM (MTGreen; Molecular Probes). Briefly, cells were washed in Ca2+-free PBS, stained 
with MitoTracker dyes and incubated for 1 hour at 37°C in the dark. CMXRos is 
incorporated into mitochondria by force of the mitochondrial membrane potential and reacts 
with thiol residues to form covalent thiol ester bonds. MTGreen FM preferentially 
accumulates in mitochondria regardless of mitochondrial membrane potential, making it a 
useful tool for determining mitochondrial mass. Samples were run on a flow cytometer 
(FACScan, Becton Dickinson) and were analyzed by the program CellQuest (Becton 
Dickinson).
Detection of intracellular ROS production
To evaluate superoxide production, cells were treated with arsenic compounds for different 
times. Twenty minutes before the cells were harvested, 10 μM dihydroethidium (Molecular 
Probes) was added to cultured cells. The cells were then washed in 2 ml Ca2+-free PBS, 
resuspended in 0.5 ml Ca2+-free PBS, and analyzed immediately for ethidium fluorescence 
intensity by flow cytometry (FACScan; Becton Dickinson).
Effects of intracellular redox status on the activity of GMZ27
The in vitro growth inhibitory effect of GMZ27 on myeloid cells was determined by the 
MTS assay (CellTiter 96R Aqueous One Solution Reagent; Promega) with or without the 
addition of L-BSO (Sigma Aldrich), which depletes GSH, or NAC (Sigma Aldrich), which 
augments cellular reduction. After a 24-hour preincubation with or without the addition of 
100 μM L-BSO or 10 mM NAC, cells were seeded in triplicate in 96-well microtiter plates 
at a density of 4×104 cells/ml. GMZ27 was added at increasing concentrations. After 72- 
hour incubation, 20 μl of MTS solution were added to each well. The cells were then 
incubated for an additional 3 hours at 37°C, and the absorbance was then measured at 490 
nM.
Analysis of cell cycle activity and subG1 DNA fragmentation status
After treatment with GMZ27, cells were collected, washed in Ca2+- free PBS, and were 
fixed overnight in 70% cold ethanol at −20°C. The cells were then washed twice in cold PBS 
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and were resuspended in Hypotonic PI solution [25 μg/ml PI, 0.1% TritonX- 100, 30 mg/ml 
(PEG), and 3600 U/ml RNAse, all dissolved in 4 mM sodium citrate buffer] for 15 minutes 
in the dark at room temperature. Collected data were analyzed by means of ModFit software 
(Becton Dickinson).
Analysis of cell maturation
The NB4 cell line was used to test the effect of ATO and GMZ27 on maturation of 
promyelocytic leukemia cells. Phycoerythrin-conjugated anti-CD11b monoclonal antibody 
(BD Pharmingen, San Diego, CA, USA) was used as a marker of leukocyte maturation. 
After 72 hours of incubation with drugs, cells (1×106 cells/ml) were washed in PBS and 
were incubated with anti- CD11b (dilution 1:10), in the dark at room temperature for 15 
minutes. After incubation, cells were washed and resuspended in 500 μl PBS. To exclude 
nonspecific binding, appropriate isotype control antibody-stained cells were prepared in the 
same manner. Cells were sorted by using a flow cytometer (FACScan; Becton Dickinson) 
and were analyzed with CellQuest software (Becton Dickinson).
Degradation of PML–RARα fusion protein
NB4 cells were treated with different concentrations of GMZ27 for 24 hours; whole cell 
lysate was then obtained and subjected to western blot as described above. Expression of 
PML–RARα was detected by polyclonal anti- PML (H-238; Santa Cruz Biotechnology, Inc, 
Santa Cruz, CA, USA). In order to ascertain whether the anti-leukemia activity of GMZ27 
depended on the degradation of the PML–RARα fusion protein, NB4 and U937 cells (a 
monocytic leukemia cell line that does not express PML–RARα) were treated with GMZ27 
and the antiproliferative effects of GMZ27 on these cell lines were evaluated by a 72-hour 
MTS assay.
Measurement of GSH content
NB4 cells (20×106) at a density of 0.4 million/ml were harvested by centrifuging at 1500 
rpm for 3 minutes. Cells were then washed with PBS once and stored at −80°C until further 
use. Three freeze-thaw cycles were performed in order to lyse the cells completely. Cell 
lysates were mixed with protein assay solution (Bio-Rad, Hercules, CA, USA) and the O.D. 
value was measured at 595 nM to determine protein concentration. Subsequently, 250 μl 
10% metaphosphase (MPA) were added to 250 μl of cell lysate, mixed, and centrifuged at 
3000 g at 4°C for 10 minutes. Next, 200 μl of supernatant were mixed with 700 μl of 
potassium phosphate buffer containing diethylenetriamine pentaacetic acid and lubrol, 
vortexed, and added to 50 μl R1 solution (4-chloro-1-methyl-7-trifluromethyl-quinolinium 
methylsulfate). After vortexing, 50 μl of R2 solution (30% NaOH) were added and the 
mixture incubated at room temperature for 10 minutes in the dark. The OD values of 
samples were measured at 400 nM.
Western blotting analysis
Following incubation with different concentrations of GMZ27 or ATO for different time 
periods western blot analysis was performed using the following primary antibodies: anti-β-
actin (Sigma Chemical Co.), anti-BCL2 (Upstate Biotechnology, Waltham, MA, USA), anti-
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BCL-xL, anti-BAX (Santa Cruz Biotechnology), anti-caspase-9, anti-caspase-8 and anti- 
(PARP) (Cell Signaling, Beverly, MA, USA), and polyclonal anti- PML (H-238; Santa Cruz, 
CA).
Results
GMZ27 induces dose-dependent inhibition of cell proliferation in leukemia cell lines
The cytotoxic properties of GMZ27 were explored in two leukemia cell lines, NB4 and 
HL60. Cell proliferation was assessed by the MTS assay 72 hours after incubation with 
GMZ27 or ATO. As shown in Figure 1A and 1B, both ATO and GMZ27 produced dose–
dependent inhibition of proliferation in both cell lines. However, GMZ27 exhibited stronger 
inhibition compared with that of ATO. The IC50 of GMZ27 ranged from 0.53 μM to 0.82 
μM when tested in various leukemia cell lines, which is significantly lower than those of 
ATO (Table I). To confirm and extend these findings, Trypan blue dye exclusion assay was 
also performed. In each cell line tested, a 72-hour treatment with GMZ27 produced 
significant dose-dependent growth inhibition (Figure 1C).
GMZ27 inhibits cell growth independently of PML–RARα expression
The aberrant PML–RARα fusion protein results from the t(15;17) translocation between the 
zinc-finger protein PML and the retinoic acid receptor α. To assess whether the effects of 
GMZ27 were mediated through inhibition/degradation of PML–RARα, NB4 cells, which 
consistently express the PML-RARα fusion protein, were treated with different doses of 
GMZ27 for 24 hours. Dose-dependent PML–RARα protein degradation upon GMZ27 
exposure was detected by western blot analysis (Figure 2A). In order to establish whether 
the PML-RARα fusion protein in leukemia cells contributed to their sensitivity to GMZ27, 
U937 cells, which do not carry PML–RARα and are known to be resistant to ATO, were 
treated with different concentrations of GMZ27 and ATO and cell proliferation was 
evaluated by the 72-hour MTS assay.
As expected, U937 cells showed significant resistance to ATO treatment. However GMZ27 
was very effective at inhibiting the proliferation of U937 cells (Figure 2B). These results 
indicated that although GMZ27 did induce degradation of PML-RARα, the antileukemia 
effect of GMZ27 was not completely dependent on the latter. We then determined whether 
the decrease in cell proliferation was associated with changes in cell maturation. Expression 
of CD11b, a maturation marker for myeloid cells, on ATO- and GMZ27-treated NB4 cells 
was analyzed by flow cytometry. We detected only a marginal increase in the percentage of 
CD11b-positive NB4 cells after a 72-hour treatment with 0.1-0.6 μM of ATO compared to 
that of GMZ27-treated cells, except when cells were treated at the highest concentration (0.6 
μM) of ATO, which induced significant induction of CD11b expression (Figure 2C).
Impact of GMZ27 on cell cycle and apoptosis in leukemia cell lines
In order to determine whether the mechanism of action of GMZ27 might involve cell cycle 
perturbations, the effects of GMZ27 on cell cycle progression were examined. To that end, 
we treated HL60 cells with different doses of GMZ27 and we analyzed the percentage of 
cells in the G2/M phase of the cell cycle as assessed by flow cytometry using PI staining. 
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The drug dose range employed was selected based on the in vitro sensitivities of the cell 
lines to GMZ27 used in the experiment. After 24-hour and 48-hour treatment with GMZ27, 
no significant induction of cell cycle arrest was observed in HL60 cells (Figure 3A). 
Similarly, no significant accumulation of cells in the sub-G1 phase of the cell cycle was 
observed at different concentrations of GMZ27 (Figure 3B).
Given the lack of significant effects on the cell cycle, we next investigated the effect of 
GMZ27 on apoptosis of HL60 cells. Cell apoptosis was assessed by flow cytometry using 
three markers directed at different targets involved in the apoptotic process: compromised 
cell membrane integrity (Figure 4A), activation of caspase 3 (Figure 4B) and dissipation of 
mitochondrial transmembrane potential (Figure 4C). By all three measures, both ATO and 
GMZ27 induced apoptosis in a concentration- and time-dependent fashion. However, 
GMZ27 induced apoptosis at significant lower concentrations compared to ATO, indicating 
a more potent proapoptotic effect associated with GMZ27.
GMZ27 induces apoptosis through activation of the intrinsic pathway and caspase 9
To determine whether induction of apoptosis in HL60 cells by GMZ27 involves activation of 
specific apoptotic pathways, HL60 cells were treated for 24 hours with vehicle or with 
GMZ27. As shown in Figure 5A, treatment with GMZ27 induced activation of caspase-9 
(demonstrated by cleavage of caspase-9), but failed to activate caspase-8. These observations 
suggest that GMZ27-mediated apoptosis may occur preferentially through the intrinsic 
apoptotic pathway, which involves activation of caspase-9 and dissipation of the 
mitochondrial transmembrane potential (Figure 4C). Furthermore, immunoblotting 
demonstrated cleavage of PARP (manifested as an 89kDa band in the western blot; Figure 
5A), thus confirming induction of apoptosis by GMZ27. To further investigate the 
mechanism of apoptosis induction, degradation of Bcl-2 family proteins (BCL-2, BCL-xl 
and BAX) was analyzed in NB4 cells treated with different concentrations of GMZ27 for 24 
hours. No significant alteration of the expression of BCL-2 proteins was detected (Figure 
5B).
The antileukemia activity of GMZ27 is dependent on modulation of intracellular oxidative 
status
Next, we evaluated the redox status of leukemia cell lines upon exposure to GMZ27. We 
modulated the cell redox status by either NAC (which enhances GSH synthesis), or by BSO 
(which blocks GSH synthesis). HL60 cells were treated with no drug, 100 μM BSO, or 10 
mM NAC for 14 hours and different concentration of GMZ27 were then added to the cell 
culture. MTS assays were performed at specific time points to evaluate cell proliferation. 
Our experiments show unequivocally that depleting intracellular GSH with BSO enhances 
the antiproliferative activity of GMZ27 (Figure 6A). This is confirmed by the fact that 
increasing cellular reduction by pre-incubation with NAC protects cells from the 
antiproliferative activity of GMZ27 (Figure 6B). The opposing effects of BSO and NAC on 
the activity of GMZ27 indicate that ROS generation is likely involved in the mechanism of 
action of GMZ27.
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To determine whether treatment with GMZ27 induced the production of ROS, superoxide 
levels were assessed in HL60 cells treated with vehicle alone, or with 1 μM GMZ27 for 0 to 
8 hours. Superoxide production increased in a dose - and time-dependent manner after 
treatment with GMZ27 that peaked at 4 hours post exposure to the drug (Figure 6C and D).
Furthermore, intracellular GSH was measured in NB4 cells after exposure to increasing 
concentrations of ATO or GMZ27. The intracellular concentration of GSH decreased 
markedly 8 hours after treatment with GMZ27 (Figure 7), which was even more remarkable 
after 14 hours (data not shown). This effect was not observed in cells treated with ATO. 
These results indicate that in addition to ROS generation, GMZ27 also further reduces 
intracellular GSH which seriously weakens the cellular antioxidant capacity, thus enhancing 
the detrimental intracellular effects of ROS. Again, similar effects on intracellular GSH were 
not observed in ATO-treated cells (data not shown).
In vivo toxicity study
In order to characterize the toxicity of GMZ27 in vivo, a single injection of this compound 
was given to wild-type Swiss-Webster mice via tail vein in groups of 6, on a 10 mg-dose 
escalating schedule with doses ranging from 0 mg/kg to 150 mg/kg. In vivo toxicity was 
measured on the basis of mortality and was expressed as the lethal dose at which half the 
mice in a group died (LD50). The LD50 was reached at 100 mg/kg, a dose significantly 
higher than that of ATO, which has been reported to be 10 mg/kg.
Discussion
The striking activity of ATO, an inorganic arsenical compound, against APL cells (7) 
resulted in the establishment of ATO as standard treatment for patients with APL. The role 
of ATO in other types of hematological cancer is, however, limited (9-12). In spite of its 
impressive activity in APL, the potential for systemic toxicity with ATO therapy is of 
concern (9-12). Inorganic arsenic compounds such as ATO affect many organ systems, 
including the cardiovascular system, gastrointestinal tract, kidneys, skin, nervous system and 
hematopoietic organs. Inorganic compounds can be particularly toxic to the liver, causing 
infiltration, central necrosis and cirrhosis (13-16). There is now sufficient evidence that 
inorganic arsenic compounds are skin and lung carcinogens in humans(16). The toxicity of a 
given arsenic compound is related to the rate of its clearance from the body and to the extent 
of its tissue accumulation (15). Unlike inorganic arsenic compounds, no deaths or serious 
toxic effects associated with OAD have been reported. In mammals, the methylation of 
inorganic arsenic has been considered as a detoxification reaction because of the lower 
toxicity of methylated OAD, and the faster excretion and reduced retention (16, 17). A good 
example is that of dimethylarsinic acid, an organic compound, which is the predominant 
urinary metabolite excreted by most mammals after exposure to inorganic arsenic, including 
ATO. The LD50 of ATO in mice is reported to be 10 mg/kg (18), while thatfor 
dimethylarsinic acid is 50-fold higher at 500 mg/kg (19). The antileukemia potential of 
melarsoprol, the only OAD currently manufactured for human use, has been evaluated. 
Studies unexpectedly showed that melarsoprol has activity at least equivalent to that of ATO 
against both APL and non- APL cell lines (20, 21). A limited clinical study of melarsoprol 
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was initiated in the U.S. in patients with advanced leukemia (22). A total of eight patients 
were treated on the schedule used for the treatment of central nervous system 
trypanosomiasis (three days per week for three consecutive weeks). Under this schedule, 
only one patient (with chronic lymphocytic leukemia) displayed antitumor effects and most 
patients experienced neurological side-effects. These early results suggest that while this or 
similar agents might have clinical benefit, the dosing schedule developed for treatment of 
trypanosomiasis is excessively toxic in patients with leukemia and that further preclinical 
experiments to develop novel OADs with equivalent activity and less toxicity would be 
necessary.
GMZ27 was picked as a leading compound among various OADs due to its potent activity 
against various kinds of tumor cell lines included in the NCI 60 cell line panel (data not 
shown). In the initial experiments presented here, cell proliferation and apoptosis were 
assayed after treatment of cells with either ATO or GMZ27. GMZ27 exhibited potent 
activity against acute leukemia cell lines, with an IC50 significantly lower than that of ATO. 
Most importantly, in in vivo experiments, GMZ27 exhibited less toxicity in wild-type mice 
than what was reported for ATO, which suggests its suitability for future clinical testing in 
leukemia. Based on these results, GMZ27 was chosen as the primary leading compound for 
further investigation regarding its antileukemic mechanism of action.
Arsenic produces profound cellular alterations, including induction of apoptosis, inhibition 
of proliferation, stimulation of differentiation, and inhibition of angiogenesis. APL is 
characterized by the t(15;17) translocation, which results in the fusion of the PML gene to 
the RARα gene (23, 24). The resulting PML–RARα fusion protein blocks the expression of 
genes required for normal myeloid differentiation. The block in myeloid differentiation by 
PML–RARα can be released by treatment with pharmacological-levels of retinoic acid, 
providing the basis for (ATRA) therapy in APL. Arsenic trioxide has been proposed as an 
alternative to treatment with ATRA because it can induce complete remission in patients 
with both RA-sensitive and RA- resistant APL. In our studies, GMZ27 and ATO (data not 
shown) can both induce degradation of the PML–RARα fusion protein. However, GMZ27 is 
effective against both NB4 cells, which express PML–RARα, as well as against U937 cells, 
which is not an APL cell line and therefore does not express PML–RARα. These results 
indicate that the main mechanism of action of GMZ27 is independent of PML–RARα 
degradation and induction of myeloid maturation, with the latter effect being similar with 
both ATO and GMZ27.
Arsenic exposure has been shown to activate caspases both in vitro and in vivo. ATO-
induced apoptosis is associated with a loss of inner mitochondrial transmembrane potential 
and release of cytochrome c into the cytosol (25-27). Other mechanisms involved in ATO-
induced apoptosis, such as a altered level of the BCL-2 family of proteins and decrease in 
telomerase transcription, remain controversial (28, 29). GMZ27 induced apoptosis in both 
APL and non-APL cell lines as evidenced by activation of caspase-3 and caspase-9, collapse 
of mitochondrial membrane potential, and PARP cleavage. However, expression of BCL-2 
family proteins, was not altered by GMZ27 treatment. It has been reported that arsenic 
treatment can induce cell cycle arrest at the G2/M checkpoint in various leukemia cell lines 
(25-27). However, cell cycle arrest at the G1 or the G2/M checkpoints was not observed upon 
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treatment of NB4 and HL60 cell lines with GMZ27. The latter indicates that although both 
inorganic and OAD contain arsenic, their mechanisms of action are different. It is well 
known that various heavy metal molecules induce oxidative damage including arsenic, iron, 
copper, nickel, chromium, cadmium, lead, and mercury (16). It is also accepted that 
induction of ROS is one of many anticancer mechanisms induced by ATO (18-20). 
Intracellular GSH constitutes the most important reductive buffer against oxidative stress 
(21, 22). Through experimental manipulations we were able to alter GSH levels that changed 
the apoptotic response of leukemia cells to GMZ27. Reduction of intracellular GSH with 
BSO in leukemia cells resulted in enhanced sensitivity to GMZ27, whereas administration of 
free radical scavengers (i.e. N-acetylcysteine) increased GSH and abrogated the cytotoxic 
effects of GMZ27 (19). In contrast with ATO, GMZ27 directly reduced the intracellular 
GSH level which made cells more sensitive to ROS-induced stress. Furthermore, GMZ27 
induced production of intracellular superoxide in a dose and time dependent manner. 
Overall, our results indicate that ROS generation is the single most important inducer of 
leukemic cell apoptosis after treatment with GMZ27.
In summary, GMZ27 inhibits proliferation and induces apoptosis of the AML cell lines 
studied here. This activity is independent of PML–RARα expression and degradation, and is 
not mediated by induction of myeloid maturation or cell cycle arrest. Instead, the activity of 
GMZ27 appears to be mediated through ROS generation and modulation of the intracellular 
oxidative status, leading to apoptosis. This novel OAD with enhanced antileukemia activity 
in vitro and a more favorable toxicity profile in vivo compared with ATO holds promise as 
an antileukemia agent.
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Figure 1. 
Activity of GMZ27 towards different leukemia cell lines. Summary of GMZ27-induced cell 
growth inhibition in 72-h MTS assays performed with HL60 (A) and NB4 (B) cells. Growth 
inhibition by GMZ27 of the HL60, NB4, U937, and KBM-5 leukemia cell lines in 72-h 
MTS assays (Table I). Viability of the HL60, NB4, U937, and KBM-5 leukemia cell lines 
after GMZ27 treatment in 72-h Trypan blue assays (C). Data represent results obtained in 
three independent experiments.
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Figure 2. 
The antileukemia effect of GMZ27 is PML–RARα independent. NB4 cells were treated 
with GMZ27 for 24 hours and dose-dependent PML–RARα protein degradation was 
assayed by western blot using a rabbit anti-PML-RARα antibody (A). NB4 and U937 cells 
were incubated with GMZ27 for 72 hours and subjected to MTS assay to evaluate cell 
proliferation. U937 was sensitive to GMZ27 but not to arsenic trioxide (ATO) (B). After 72 
hours of incubation with GMZ27 or ATO, NB4 cells were incubated with phycoerythrin-
conjugated anti-CD11b monoclonal antibody (dilution 1:10) and then subjected to flow 
cytometry analysis using CellQuest software. GMZ27 treatment induces marginal myeloid 
maturation compared to ATO (C).
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Figure 3. 
GMZ27 does not induce cell cycle arrest. HL60 cells were treated with GMZ27 for 24 and 
48 hours. Cell cycle analysis showed no arrest. The percentage of Sub G1 phase of cells after 
treatment with of GMZ27 is also presented (B).
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Figure 4. 
GMZ27 induces apoptosis of HL60 cells in a dose- and time-dependent manner. HL60 cells 
were treated with ATO or GMZ27 for 24 h and 48 h and apoptosis was evaluated by flow 
cytometry. Different aspects of the apoptotic process were analyzed. (A) Compromised cell 
membrane integrity (annexin V/PI staining). (B) Caspase activation (PhiPhiLux/PI assay). 
(C) Dissipation of mitochondrial transmembrane potential (CMXRos/MTGreen staining). 
Representative data are shown from experiments performed in triplicate.
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Figure 5. 
GMZ27 induces apoptosis in HL60 cells through activation of caspase-9. After incubation 
with GMZ27 for 24 hours, whole-cell lysate was subjected to western blot to detect pro-
caspase-8, pro-caspase-9 and their active, cleaved fragments. PARP cleavage was also 
detected by western blotting. GMZ27-mediated apoptosis occurs preferentially through the 
intrinsic apoptosis pathway (A). GMZ27 does not alter the expression levels of Bcl-2, BAX 
and BCL-xl. Expressions of BCL family proteins were detected by anti-BCL-2, anti-BCL-xl 
and anti-BAX antibodies. β-Actin expression was detected by the anti-β-Actin antibody and 
was used as loading control (B).
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Figure 6. 
The antileukemia activity of GMZ27 is mediated through modulation of intracellular 
oxidative status and production of reactive oxygen species (ROS). HL60 cells were pre-
incubated with or without 100 μM L-buthionine-[S,R]-sulfoximine (L-BSO) (A) or 10 mM 
N-acetyl-L-cysteine (NAC) (B) for 24 hours, and were then treated with GMZ27 at different 
concentrations. After 72 hours MTS assay was performed in order to evaluate cell 
proliferation. GMZ27 treatment results in production of superoxide. HL60 cells were treated 
with GMZ27 for 2, 4, 6, 8 hours. Superoxide production was assessed using a 
dihydroethidium probe. Each experimental point represents the mean±SD of three 
independent experiments (C, D).
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Figure 7. 
GMZ27 treatment depletes intracellular GSH content in NB4 cells. After 2, 8, 14, 24 hours 
of GMZ27 treatment, 20×106 NB4 cells were harvested and the intracellular GSH was 
measured with 4-chloro-1-methyl-7-trifluromethyl-quinolinium methylsulfate as per the 
manufacturer’s instructions. The GSH content is expressed as μmol/μg protein.
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Table I
IC50 of GMZ27 tested in various leukemia cell lines.
Cell line IC50 (μM)
HL60 0.79±0.22
NB4 0.5±0.18
U937 0.82±0.31
KBM-5 0.77±0.15
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